safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI) in diabetes mellitus in the following categories: (a) in adults ...

The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30 ... a good body of evidence relating to its use in different dosage regimens and in comparison with other insulin treatment ...

Unfortunately, the current drug pricing bill fails to take a holistic ... s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart ... They will use drug substance made by GeneSys Biologics ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

If your body cannot make or use insulin effectively, you need to inject it to process your food for energy. Calculating a bolus dose is where insulin administration can get tricky. When you give y ...

If you’re interested in Zepbound, talk with your doctor or pharmacist. Will my insulin dose change when I start receiving Mounjaro? If insulin is part of your treatment plan, your doctor may ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.